DK1425037T3 - Bakteriel vaccine - Google Patents

Bakteriel vaccine

Info

Publication number
DK1425037T3
DK1425037T3 DK02755355T DK02755355T DK1425037T3 DK 1425037 T3 DK1425037 T3 DK 1425037T3 DK 02755355 T DK02755355 T DK 02755355T DK 02755355 T DK02755355 T DK 02755355T DK 1425037 T3 DK1425037 T3 DK 1425037T3
Authority
DK
Denmark
Prior art keywords
attenuated
bacteria
enterotoxins
bacterial vaccine
provides strains
Prior art date
Application number
DK02755355T
Other languages
English (en)
Inventor
Arthur Keith Turner
Judith Greenwood
Jonathan Stephens
Juliet Claire Beavis
Michael James Darsley
Original Assignee
Acambis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9921935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1425037(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acambis Res Ltd filed Critical Acambis Res Ltd
Application granted granted Critical
Publication of DK1425037T3 publication Critical patent/DK1425037T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02755355T 2001-09-11 2002-09-11 Bakteriel vaccine DK1425037T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0121998.9A GB0121998D0 (en) 2001-09-11 2001-09-11 Attenuated bacteria useful in vaccines

Publications (1)

Publication Number Publication Date
DK1425037T3 true DK1425037T3 (da) 2006-03-27

Family

ID=9921935

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02755355T DK1425037T3 (da) 2001-09-11 2002-09-11 Bakteriel vaccine
DK02755363.5T DK1425038T4 (da) 2001-09-11 2002-09-11 Svækkede bakterier, der er anvendelige i vacciner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02755363.5T DK1425038T4 (da) 2001-09-11 2002-09-11 Svækkede bakterier, der er anvendelige i vacciner

Country Status (10)

Country Link
US (4) US7951361B2 (da)
EP (2) EP1425038B2 (da)
AT (2) ATE308992T1 (da)
AU (2) AU2002321652B2 (da)
CA (2) CA2459586A1 (da)
DE (2) DE60207278T3 (da)
DK (2) DK1425037T3 (da)
ES (2) ES2256514T3 (da)
GB (1) GB0121998D0 (da)
WO (2) WO2003022306A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7468269B2 (en) * 2003-02-26 2008-12-23 University Of Massachusetts Reagents for recombinogenic engineering and uses thereof
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
EP1543836A1 (en) * 2003-12-17 2005-06-22 Berna Biotech AG Recombinant Vibrio cholerae strain and vaccine comprising said strain
US7759106B2 (en) 2004-05-19 2010-07-20 The United States Of America As Represented By The Secretary Of The Army Construction of live attenuated Shigella vaccine strains that express CFA/I antigens (CfaB and CfaE) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic E. coli
EP2471549A1 (en) * 2005-01-11 2012-07-04 The United States of America as represented by The Secretary of The Navy Adhesin as immunogen against Escherichia coli
FR2890859B1 (fr) * 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
WO2009004002A1 (en) * 2007-07-02 2009-01-08 Sbl Vaccin Ab Hybrid operon for expression of colonization factor (cf) antigens of enterotoxigenic escherichia coli
US9410157B2 (en) 2010-07-30 2016-08-09 Wisconsin Alumni Research Foundation Systems and methods for the secretion of recombinant proteins in gram negative bacteria
CN103917244B (zh) 2011-09-12 2016-07-06 斯堪的纳维亚生物制药控股公司 用于提高细胞表面的etec cs6抗原呈递的方法及可由其获得的产物
WO2014047625A1 (en) 2012-09-24 2014-03-27 Montana State University Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
WO2014077977A1 (en) * 2012-11-19 2014-05-22 The United States Of America As Represented By The Secretary Of The Navy Recombinant polypeptide construct comprising multiple enterotoxigenic escherichia coli fimbrial subunits
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
CA2966754A1 (en) 2014-11-05 2016-05-12 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
CN105063073A (zh) * 2015-09-16 2015-11-18 中国科学院南海海洋研究所 一种弧菌通用的基因敲除自杀载体及其应用
US11471520B2 (en) * 2018-04-03 2022-10-18 University Of Maryland, Baltimore Enhanced Shigella-enterotoxigenic E. coli multi-valent vaccine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58146596A (ja) * 1982-02-25 1983-09-01 Takeda Chem Ind Ltd 組換えｄｎａ、それで形質転換させた微生物およびそれらの用途
US4935364A (en) * 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
SE9100556D0 (sv) 1991-02-26 1991-02-26 Holmgren Jan Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
AU664360B2 (en) 1991-03-05 1995-11-16 Wellcome Foundation Limited, The Expression of recombinant proteins in attenuated bacteria
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US7404961B2 (en) * 1996-08-02 2008-07-29 The United States Of America As Represented By The Secretary Of The Army Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
SE9801852D0 (sv) 1998-05-26 1998-05-26 Sbl Vaccin Ab Method of producing thy A-strains of Vibro cholerae, suck strains and their use
SE515285C2 (sv) * 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
EP1216303A1 (en) * 1999-09-15 2002-06-26 Mogam Biotechnology Research Institute Novel detoxified mutants of escherichia coli heat-labile enterotoxin
MXPA02010407A (es) * 2000-04-20 2003-05-23 Univ Maryland Aislamiento y caracterizacion del operante csa (etec-cs4-pili) y metodos para su uso.
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
US20120064114A1 (en) * 2008-10-21 2012-03-15 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
WO2011002836A2 (en) * 2009-06-30 2011-01-06 Stc.Unm Attenuated enterohemorrhagic e.coli-based vaccine vector and methods relating thereto

Also Published As

Publication number Publication date
DE60207278T2 (de) 2006-08-10
AU2002321652B2 (en) 2008-04-10
EP1425038B2 (en) 2010-09-01
CA2459586A1 (en) 2003-03-20
ATE308992T1 (de) 2005-11-15
WO2003022306A3 (en) 2003-06-26
ATE308991T1 (de) 2005-11-15
EP1425037B1 (en) 2005-11-09
ES2256515T3 (es) 2006-07-16
ES2256514T3 (es) 2006-07-16
DK1425038T3 (da) 2006-03-27
DE60207278T3 (de) 2011-05-05
EP1425038A1 (en) 2004-06-09
US20040253710A1 (en) 2004-12-16
US20110200638A1 (en) 2011-08-18
ES2256515T5 (es) 2011-02-25
EP1425038B1 (en) 2005-11-09
DE60207278D1 (de) 2005-12-15
US8318148B2 (en) 2012-11-27
US20110189225A1 (en) 2011-08-04
DE60207277T2 (de) 2006-08-03
WO2003022307A1 (en) 2003-03-20
DE60207277D1 (de) 2005-12-15
EP1425037A2 (en) 2004-06-09
GB0121998D0 (en) 2001-10-31
AU2002321644B2 (en) 2008-03-13
CA2460025A1 (en) 2003-03-20
US20050054075A1 (en) 2005-03-10
US7943122B2 (en) 2011-05-17
US7951361B2 (en) 2011-05-31
DK1425038T4 (da) 2010-12-13
WO2003022306A2 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
DE60207277D1 (de) Bakterieller impfstoff
ATE357249T1 (de) Auf bläschen basierendes impfstoff gegen chlamydia
WO2002009746A3 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
MA29459B1 (fr) Vaccins
NO20004781D0 (no) Svekkede bakterier anvendelige i vaksiner
WO2000037609A3 (en) Orally immunogenic bacterial enterotoxins expressed in transgenic plants
WO2002034773A3 (en) Streptococcal genes
HU0005010D0 (da)
DK1154791T3 (da) Neisseria-vaccinesammensætninger og fremgangsmåder
EP1908839A3 (en) Virulence genes, proteins, and their use
NO20062469L (no) Streptococcus phocae vaksine
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
DE602004031127D1 (de) Attenuierte bakterielle lebendvakzine
RU2002122063A (ru) Штам бактерий leptospira interrogans "митронов" серогруппы canicola для приготовления вакцины
AU2001258579A1 (en) Virulence genes, proteins, and their use
DE60238554D1 (de) Vakzine gegen infektionskrankheiten
CY1117291T1 (el) Εμβολιο κατα του ροταϊου
RU2001132094A (ru) Штамм бактерий Escherichia coli № 28 09:K99, используемый для изготовления вакцин и диагностических препаратов
RU99117152A (ru) Штамм бактерий pseudomonas aeruginosa 4492, используемый для изготовления вакцины против псевдомоноза пушных зверей
RU99117155A (ru) Штамм бактерий pseudomonas aeruginosa 5292, используемый для изготовления вакцины против псевдомоноза пушных зверей
RU99117153A (ru) Штамм бактерий pseudomonas aeruginosa 4762, используемый для изготовления вакцины против псевдомоноза пушных зверей
RU2003110247A (ru) Штамм escherichia coli б-5, используемый для получения термолабильного экзотоксина
RU2002129867A (ru) Штамм бактерий escherichia coli км 148-продуцент протективных антигенов, используемый для иммунопрофилактики колибактериоза и холеры
RU99117151A (ru) Штамм бактерий pseudomonas aeruginosa 5002, используемый для изготовления вакцины против псевдомоноза пушных зверей